This good practice paper focuses on the use of genetic and genomic tests for adult chronic myeloid neoplasms as defined by the World Health Organisation, including myeloproliferative neoplasms (MPN), myelodysplastic/myeloproliferative neoplasms (MDS/NPN), myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2 (myeloid/lymphoid neoplasms with eosinophilia, MLN- eo) and mastocytosis. We have not included chronic myeloid leukaemia (CML) as this has been covered recently elsewhere, as has the full spectrum of clinical and laboratory investigations for patients with abnormal blood counts and/or suspected myeloid neoplasia.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.